For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

22nd Jun 10

Pharmaxis Announces Results for Second Phase III Trial of Bronchitol in Cystic Fibrosis

Pharmaxis is pleased to announce top line results from the second large-scale global Phase III trial (CF302) of Bronchitol® (mannitol inhalation powder) in patients with cystic fibrosis (CF).

The results support the early and sustained improvement in lung function in cystic fibrosis patients seen in the first phase III study (CF301) and Pharmaxis will now move forward to meet the U.S. Food & Drug Administration (FDA) later this year to discuss a New Drug Application (NDA) for Bronchitol.


Read full media release - pdf
22nd Jun 10

Investor Conference Call - Clinical Trial Results

Pharmaxis Ltd expects to complete its analysis and announce the results of its second international Phase III clinical trial of Bronchitol in patients with cystic fibrosis prior to the end of today, 22 June 2010. The announcement will have the effect of lifting the current trading halt over the company's shares.


18th Jun 10

Pharmaxis CEO

The Chairman of the Pharmaxis Ltd Board, Mr Denis Hanley advises that the company's Chief Executive Officer Dr Alan Robertson has undergone a medical procedure.  Dr Robertson is expected to make a full recovery but will be absent from the office for the next few weeks.


Read full media release - pdf